A single-arm, investigator-initiated study of the efficacy, safety, and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration previously treated with ranibizumab or bevacizumab (ASSESS study): 12-month analysis
Rishi P Singh, Sunil K Srivastava, Justis P Ehlers, Fabiana Q Silva, Rumneek Bedi, Andrew P Schachat, Peter K Kaiser Cole Eye Institute, Cleveland Clinic, Cleveland, OH, USA Summary statement: In subjects with active exudative age-related macular degeneration, treating with a fixed intravitreal af...
Guardado en:
| Autores principales: | , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2015
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/11c4bed5a9734a1581ec3cafd4751162 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:11c4bed5a9734a1581ec3cafd4751162 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:11c4bed5a9734a1581ec3cafd47511622021-12-02T00:04:39ZA single-arm, investigator-initiated study of the efficacy, safety, and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration previously treated with ranibizumab or bevacizumab (ASSESS study): 12-month analysis1177-5483https://doaj.org/article/11c4bed5a9734a1581ec3cafd47511622015-09-01T00:00:00Zhttps://www.dovepress.com/a-single-arm-investigator-initiated-study-of-the-efficacy-safety-and-t-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Rishi P Singh, Sunil K Srivastava, Justis P Ehlers, Fabiana Q Silva, Rumneek Bedi, Andrew P Schachat, Peter K Kaiser Cole Eye Institute, Cleveland Clinic, Cleveland, OH, USA Summary statement: In subjects with active exudative age-related macular degeneration, treating with a fixed intravitreal aflibercept injection dosing regimen for 12 months demonstrated improved anatomic and vision endpoints from baseline.Purpose: Switching therapies in neovascular age-related macular degeneration (AMD) may offer an advantage for some patients. This study evaluates the efficacy of intravitreal aflibercept injection (IAI) in subjects previously treated with ranibizumab and/or bevacizumab.Methods: Subjects (n=26) were given monthly 2 mg of IAI for 3 months, followed by 2 mg once in every 2 months for up to 12 months. The mean absolute change from baseline in central subfield thickness (CST) measured by optical coherence tomography and the mean change from baseline in best-corrected visual acuity (BCVA) early treatment in diabetic retinopathy study (ETDRS) letter score were obtained. Additionally, the percentage of subjects who gained or lost ≥15 letters of vision and the percentage of subjects who are 20/40 or better or 20/200 or worse were evaluated.Results: There was a mean decrease in CST of -50.3 µm (P<0.001) and a mean increase in ETDRS BCVA of +9.2 letters (P<0.001). Twenty-seven percent of subjects experienced a ≥15-letter improvement in visual acuity, and no subject lost ≥3 lines of vision from baseline. Fifty percent of subjects were 20/40 or better, and 11.5% of subjects were 20/200 or worse at month 12.Conclusion: Fixed IAI dosing regimen for 12 months demonstrated improved anatomic and vision endpoints in subjects with active exudative AMD. Keywords: aflibercept, age-related macular degeneration, bevacizumab, ranibizumab, vascular endothelial growth factorsSingh RPSrivastava SKEhlers JPSilva FQBedi RSchachat APKaiser PKDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2015, Iss default, Pp 1759-1766 (2015) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Ophthalmology RE1-994 |
| spellingShingle |
Ophthalmology RE1-994 Singh RP Srivastava SK Ehlers JP Silva FQ Bedi R Schachat AP Kaiser PK A single-arm, investigator-initiated study of the efficacy, safety, and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration previously treated with ranibizumab or bevacizumab (ASSESS study): 12-month analysis |
| description |
Rishi P Singh, Sunil K Srivastava, Justis P Ehlers, Fabiana Q Silva, Rumneek Bedi, Andrew P Schachat, Peter K Kaiser Cole Eye Institute, Cleveland Clinic, Cleveland, OH, USA Summary statement: In subjects with active exudative age-related macular degeneration, treating with a fixed intravitreal aflibercept injection dosing regimen for 12 months demonstrated improved anatomic and vision endpoints from baseline.Purpose: Switching therapies in neovascular age-related macular degeneration (AMD) may offer an advantage for some patients. This study evaluates the efficacy of intravitreal aflibercept injection (IAI) in subjects previously treated with ranibizumab and/or bevacizumab.Methods: Subjects (n=26) were given monthly 2 mg of IAI for 3 months, followed by 2 mg once in every 2 months for up to 12 months. The mean absolute change from baseline in central subfield thickness (CST) measured by optical coherence tomography and the mean change from baseline in best-corrected visual acuity (BCVA) early treatment in diabetic retinopathy study (ETDRS) letter score were obtained. Additionally, the percentage of subjects who gained or lost ≥15 letters of vision and the percentage of subjects who are 20/40 or better or 20/200 or worse were evaluated.Results: There was a mean decrease in CST of -50.3 µm (P<0.001) and a mean increase in ETDRS BCVA of +9.2 letters (P<0.001). Twenty-seven percent of subjects experienced a ≥15-letter improvement in visual acuity, and no subject lost ≥3 lines of vision from baseline. Fifty percent of subjects were 20/40 or better, and 11.5% of subjects were 20/200 or worse at month 12.Conclusion: Fixed IAI dosing regimen for 12 months demonstrated improved anatomic and vision endpoints in subjects with active exudative AMD. Keywords: aflibercept, age-related macular degeneration, bevacizumab, ranibizumab, vascular endothelial growth factors |
| format |
article |
| author |
Singh RP Srivastava SK Ehlers JP Silva FQ Bedi R Schachat AP Kaiser PK |
| author_facet |
Singh RP Srivastava SK Ehlers JP Silva FQ Bedi R Schachat AP Kaiser PK |
| author_sort |
Singh RP |
| title |
A single-arm, investigator-initiated study of the efficacy, safety, and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration previously treated with ranibizumab or bevacizumab (ASSESS study): 12-month analysis |
| title_short |
A single-arm, investigator-initiated study of the efficacy, safety, and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration previously treated with ranibizumab or bevacizumab (ASSESS study): 12-month analysis |
| title_full |
A single-arm, investigator-initiated study of the efficacy, safety, and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration previously treated with ranibizumab or bevacizumab (ASSESS study): 12-month analysis |
| title_fullStr |
A single-arm, investigator-initiated study of the efficacy, safety, and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration previously treated with ranibizumab or bevacizumab (ASSESS study): 12-month analysis |
| title_full_unstemmed |
A single-arm, investigator-initiated study of the efficacy, safety, and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration previously treated with ranibizumab or bevacizumab (ASSESS study): 12-month analysis |
| title_sort |
single-arm, investigator-initiated study of the efficacy, safety, and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration previously treated with ranibizumab or bevacizumab (assess study): 12-month analysis |
| publisher |
Dove Medical Press |
| publishDate |
2015 |
| url |
https://doaj.org/article/11c4bed5a9734a1581ec3cafd4751162 |
| work_keys_str_mv |
AT singhrp asinglearminvestigatorinitiatedstudyoftheefficacysafetyandtolerabilityofintravitrealafliberceptinjectioninsubjectswithexudativeagerelatedmaculardegenerationpreviouslytreatedwithranibizumaborbevacizumabassessstudy12monthanalysis AT srivastavask asinglearminvestigatorinitiatedstudyoftheefficacysafetyandtolerabilityofintravitrealafliberceptinjectioninsubjectswithexudativeagerelatedmaculardegenerationpreviouslytreatedwithranibizumaborbevacizumabassessstudy12monthanalysis AT ehlersjp asinglearminvestigatorinitiatedstudyoftheefficacysafetyandtolerabilityofintravitrealafliberceptinjectioninsubjectswithexudativeagerelatedmaculardegenerationpreviouslytreatedwithranibizumaborbevacizumabassessstudy12monthanalysis AT silvafq asinglearminvestigatorinitiatedstudyoftheefficacysafetyandtolerabilityofintravitrealafliberceptinjectioninsubjectswithexudativeagerelatedmaculardegenerationpreviouslytreatedwithranibizumaborbevacizumabassessstudy12monthanalysis AT bedir asinglearminvestigatorinitiatedstudyoftheefficacysafetyandtolerabilityofintravitrealafliberceptinjectioninsubjectswithexudativeagerelatedmaculardegenerationpreviouslytreatedwithranibizumaborbevacizumabassessstudy12monthanalysis AT schachatap asinglearminvestigatorinitiatedstudyoftheefficacysafetyandtolerabilityofintravitrealafliberceptinjectioninsubjectswithexudativeagerelatedmaculardegenerationpreviouslytreatedwithranibizumaborbevacizumabassessstudy12monthanalysis AT kaiserpk asinglearminvestigatorinitiatedstudyoftheefficacysafetyandtolerabilityofintravitrealafliberceptinjectioninsubjectswithexudativeagerelatedmaculardegenerationpreviouslytreatedwithranibizumaborbevacizumabassessstudy12monthanalysis AT singhrp singlearminvestigatorinitiatedstudyoftheefficacysafetyandtolerabilityofintravitrealafliberceptinjectioninsubjectswithexudativeagerelatedmaculardegenerationpreviouslytreatedwithranibizumaborbevacizumabassessstudy12monthanalysis AT srivastavask singlearminvestigatorinitiatedstudyoftheefficacysafetyandtolerabilityofintravitrealafliberceptinjectioninsubjectswithexudativeagerelatedmaculardegenerationpreviouslytreatedwithranibizumaborbevacizumabassessstudy12monthanalysis AT ehlersjp singlearminvestigatorinitiatedstudyoftheefficacysafetyandtolerabilityofintravitrealafliberceptinjectioninsubjectswithexudativeagerelatedmaculardegenerationpreviouslytreatedwithranibizumaborbevacizumabassessstudy12monthanalysis AT silvafq singlearminvestigatorinitiatedstudyoftheefficacysafetyandtolerabilityofintravitrealafliberceptinjectioninsubjectswithexudativeagerelatedmaculardegenerationpreviouslytreatedwithranibizumaborbevacizumabassessstudy12monthanalysis AT bedir singlearminvestigatorinitiatedstudyoftheefficacysafetyandtolerabilityofintravitrealafliberceptinjectioninsubjectswithexudativeagerelatedmaculardegenerationpreviouslytreatedwithranibizumaborbevacizumabassessstudy12monthanalysis AT schachatap singlearminvestigatorinitiatedstudyoftheefficacysafetyandtolerabilityofintravitrealafliberceptinjectioninsubjectswithexudativeagerelatedmaculardegenerationpreviouslytreatedwithranibizumaborbevacizumabassessstudy12monthanalysis AT kaiserpk singlearminvestigatorinitiatedstudyoftheefficacysafetyandtolerabilityofintravitrealafliberceptinjectioninsubjectswithexudativeagerelatedmaculardegenerationpreviouslytreatedwithranibizumaborbevacizumabassessstudy12monthanalysis |
| _version_ |
1718403909990481920 |